Ivantis completion of financing novel glaucoma procedure

Article

Ivantis announced the completion of financing $27 million for a novel glaucoma procedure at the Glaucoma Research Foundation's latest meeting.

Ivantis announced the completion of financing $27 million for a novel glaucoma procedure at the Glaucoma Research Foundation's latest meeting.

The funding will support four international, randomized, prospective, controlled multi-centre trials, including an ongoing United States trial.

The Series B funding round, led by Ascension Health Ventures (AHV), included returning investors New Enterprise Associates (NEA) and Delphi Ventures, along with new investors MemorialCare Innovation Fund.

Dr Tara Butler, Investment Director at AHV, commented, "AHV is pleased to lead Ivantis’s latest round of financing. As a disease, glaucoma is already one of the most vexing issues in our healthcare system today, and its prevalence is projected to double in the U.S. by 2030. With over half of all glaucoma patients in the U.S. not taking their medications consistently, if at all, this poses not only a medical challenge, but also a socioeconomic burden."

"This investment decision was driven by high-calibre clinical data, a strong intellectual property position and obvious clinician conviction for the promise of this technology," she added, "Our limited partners’ expertise as leading healthcare providers, coupled with Ivantis’s premier technology and outstanding leadership team, made this a highly attractive and synergistic investment opportunity for us."

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.